Shares of Shield Therapeutics PLC (LON:STX) hit a new 52-week high on Wednesday . The stock traded as high as GBX 119.50 ($1.56) and last traded at GBX 115 ($1.50), with a volume of 381841 shares changing hands. The stock had previously closed at GBX 114.50 ($1.50).
Several brokerages recently weighed in on STX. FinnCap began coverage on Shield Therapeutics in a research note on Tuesday, May 14th. They set a “corporate” rating and a GBX 200 ($2.61) target price for the company. Peel Hunt reaffirmed a “buy” rating on shares of Shield Therapeutics in a research report on Thursday, May 2nd. Finally, Liberum Capital reaffirmed a “buy” rating on shares of Shield Therapeutics in a research report on Wednesday, April 3rd.
The stock has a market cap of $128.85 million and a PE ratio of -74.11.
Shield Therapeutics Company Profile (LON:STX)
Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.
Recommended Story: Overbought
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.